Recent Updates
Recently added Catalysts

INC424

Phase 3

Myelofibrosis | Small molecule | Other |Novartis AG|Last Updated: Apr 26, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment2,233
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01493414INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.PHASE3 COMPLETED 2,233Aug 16, 2011Jan 26, 2017Apr 26, 2019273 Algeria, Argentina +23
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years
Baseline up to approximately 5 years

An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above.

Secondary Endpoints
Percentage of Participants With at Least 50% Reduction in Spleen Length
Baseline up to approximately 5 years
Number of Participants With Best Overall Response (BOR) up to 5 Years According to Spleen Length
Baseline up to approximately 5 years
Change in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to Worst Post-baseline ECOG Status up to 5 Years
Baseline up to approximately 5 years
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
INC424EXPERIMENTAL5 - 25 mg twice a day (BID)
Interventions
NameTypeDescription
INC424DRUGAll patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites273

Main Inclusion Criteria: 1. Patients must not be eligible for another ongoing INC424 clinical trial. 2. Patients must be diagnosed with PMF, PPV MF or PET-MF, according to the 2008 revised International Standard Criteria, irrespective of JAK2 mutation status.. 3. Patients with PMF requiring therapy...

Countries:AlgeriaArgentinaAustriaBelgiumBrazilCanadaColombiaCzechiaGermanyGreeceHungaryIrelandIsraelItalyMexicoMoroccoPolandPortugalRussiaSaudi ArabiaSlovakiaSouth AfricaSpainThailandTunisia
Unlock Eligibility Criteria